Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03149003 · ClinicalTrials.gov registry record · Phase 3
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 221
- Enrollment target
NCT03149003 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 221 participants.
The verdict
NCT03149003, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 221 participants
- Enrollment target
Study Summary
This is an event driven, adaptive design, a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 3 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.
Interventions
- DRUG Bevacizumab
- DRUG DSP-7888 Dosing Emulsion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2017-12-08 |
| Est. Completion | 2021-08-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03149003
The ClinicalTrials.gov registry entry for NCT03149003 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT03149003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03149003 about?
NCT03149003 is a clinical study titled "A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy". This is an event driven, adaptive design, a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 3 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with fi...
What is the current status of trial NCT03149003?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 221 participants. The study started on 2017-12-08. Estimated completion is 2021-08-30.
What interventions are being tested in trial NCT03149003?
The interventions under investigation include: Bevacizumab (DRUG), DSP-7888 Dosing Emulsion (DRUG).
Who is sponsoring clinical trial NCT03149003?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.